±á³Ü²¹?²Ñ±ð»å¾±³¦¾±²Ô±ð?("³Ù³ó±ð?°ä´Ç³¾±è²¹²Ô²â",?±á´Ç²Ô²µ?°´Ç²Ô²µ?³§³Ù´Ç³¦°ì?·¡³æ³¦³ó²¹²Ô²µ±ð?³§³Ù´Ç³¦°ì?°ä´Ç»å±ð:?2552.±á°)?²¹²Ô²Ô´Ç³Ü²Ô³¦±ð»å?³Ù´Ç»å²¹²â?³Ù³ó²¹³Ù?¾±³Ù²õ?²µ±ô´Ç²ú²¹±ô?´Ú¾±°ù²õ³Ù-¾±²Ô-³¦±ô²¹²õ²õ?²µ±ô³Ü³¦´Ç°ì¾±²Ô²¹²õ±ð?²¹³¦³Ù¾±±¹²¹³Ù´Ç°ù?(³Ò°´¡)?»å´Ç°ù³ú²¹²µ±ô¾±²¹³Ù¾±²Ô?(°Õ°ù²¹»å±ð?²Ô²¹³¾±ð:?²Ñ³Û±á°¿²Ñ³§±õ³§?,?»ªÁìƬ?)?³ó²¹²õ?²ú±ð±ð²Ô?²¹±è±è°ù´Ç±¹±ð»å?´Ú´Ç°ù?³¾²¹°ù°ì±ð³Ù¾±²Ô²µ?²ú²â?³Ù³ó±ð?±Ê³ó²¹°ù³¾²¹³¦±ð³Ü³Ù¾±³¦²¹±ô?³§±ð°ù±¹¾±³¦±ð?´Ç´Ú?³Ù³ó±ð?¶Ù±ð±è²¹°ù³Ù³¾±ð²Ô³Ù?´Ç´Ú?±á±ð²¹±ô³Ù³ó?´Ç´Ú?³Ù³ó±ð?±á´Ç²Ô²µ?°´Ç²Ô²µ?³§±è±ð³¦¾±²¹±ô?´¡»å³¾¾±²Ô¾±²õ³Ù°ù²¹³Ù¾±±¹±ð?¸é±ð²µ¾±´Ç²Ô?´Ç´Ú?°ä³ó¾±²Ô²¹?´Ú´Ç°ù?³Ù³ó±ð?³Ù°ù±ð²¹³Ù³¾±ð²Ô³Ù?´Ç´Ú?°Õ²â±è±ð?2?»å¾±²¹²ú±ð³Ù±ð²õ?¾±²Ô?²¹»å³Ü±ô³Ù²õ.
Hua?Medicine?("the?Company",?Hong?Kong?Stock?Exchange?Stock?Code:?2552.HK)?announced?that?the?multiple-ascending?dose?(MAD)?Phase?Ib?clinical?trial?of?HMS1005?(formerly?known?as?HM-002-1005),?a?second-generation?glucokinase?activator?(GKA)?independently?developed?by?the?Company,?has?successfully?completed?the?first?patient?dosing?in?the?United?States.
Recently,?the?Shanghai?Municipal?People's?Government?officially?announced?the?winners?of?the?Fifth?Shanghai?Intellectual?Property?Innovation?Awards.?Hua?Medicine?was?honored?with?the?Shanghai?IPR?Innovation?Award?(first?prizes?for?patents)?for?its?Chinese?invention?patent?titled?"Oral?preparation?of?glucokinase?activator?and?preparation?method?therefor".?This?recognition?establishes?the?Company?as?a?leading?enterprise?in?intellectual?property?innovation?within?the?biopharmaceutical?industry.
ir@huamedicine.com
No.275 Ai Di Sheng Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203
Privacy Statement Terms of Use
